CR20210285A - DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVIDADES DE CANALES DE POTASIO Kv3 - Google Patents

DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVIDADES DE CANALES DE POTASIO Kv3

Info

Publication number
CR20210285A
CR20210285A CR20210285A CR20210285A CR20210285A CR 20210285 A CR20210285 A CR 20210285A CR 20210285 A CR20210285 A CR 20210285A CR 20210285 A CR20210285 A CR 20210285A CR 20210285 A CR20210285 A CR 20210285A
Authority
CR
Costa Rica
Prior art keywords
arylsulfonylpyrolecarboxamide
derivatives
potassium channel
channel activators
compounds
Prior art date
Application number
CR20210285A
Other languages
English (en)
Inventor
Lars Kyhn Rasmussen
Wanwan Yu
Anette Graven Sams
Paul Robert Fleming
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CR20210285A publication Critical patent/CR20210285A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos novedosos que activan los canales de potasio Kv3. Los compuestos tienen la estructura <img src="data:image/png;base64,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 (***)
CR20210285A 2018-10-30 2019-10-30 DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVIDADES DE CANALES DE POTASIO Kv3 CR20210285A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201800787 2018-10-30
PCT/EP2019/079587 WO2020089262A1 (en) 2018-10-30 2019-10-30 Arylsulfonylpyrolecarboxamide derivatives as kv3 potassium channel activators

Publications (1)

Publication Number Publication Date
CR20210285A true CR20210285A (es) 2021-09-16

Family

ID=70327875

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210285A CR20210285A (es) 2018-10-30 2019-10-30 DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVIDADES DE CANALES DE POTASIO Kv3

Country Status (24)

Country Link
US (1) US20200131156A1 (es)
EP (1) EP3873891A1 (es)
JP (1) JP2022509416A (es)
KR (1) KR20210086661A (es)
CN (1) CN113056461A (es)
AR (1) AR116898A1 (es)
AU (1) AU2019373367A1 (es)
BR (1) BR112020013011A2 (es)
CA (1) CA3116273A1 (es)
CL (1) CL2021001123A1 (es)
CO (1) CO2021005579A2 (es)
CR (1) CR20210285A (es)
DO (1) DOP2021000081A (es)
EA (1) EA202190899A1 (es)
EC (1) ECSP21038534A (es)
IL (1) IL282639A (es)
JO (1) JOP20210091A1 (es)
MA (1) MA54061A (es)
MX (1) MX2021004935A (es)
PE (1) PE20211975A1 (es)
PH (1) PH12021550957A1 (es)
SG (1) SG11202104348XA (es)
TW (1) TW202031645A (es)
WO (1) WO2020089262A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
CN113692405A (zh) * 2019-04-26 2021-11-23 H.隆德贝克有限公司 作为kv3钾通道激活剂的n-((杂芳基)甲基)-1-甲苯磺酰基-1h-吡唑-3-甲酰胺的衍生物用于治疗神经或精神障碍
US20240327406A1 (en) 2021-08-10 2024-10-03 Autifony Therapeutics Limited Potassium channel modulators
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003921A1 (en) * 2007-07-04 2009-01-08 Neurosearch A/S Novel pyrazole derivatives useful as potassium channel modulators
TW201028421A (en) * 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
WO2011073269A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Piperidine aryl sulfonamide derivatives as kv1.3 modulators
WO2011073276A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
FR2967674B1 (fr) * 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
JP5989805B2 (ja) * 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
US9422252B2 (en) * 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) * 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) * 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
US20200131156A1 (en) 2020-04-30
MA54061A (fr) 2021-12-15
IL282639A (en) 2021-06-30
CO2021005579A2 (es) 2021-05-10
MX2021004935A (es) 2021-06-08
PH12021550957A1 (en) 2022-05-02
CA3116273A1 (en) 2020-05-07
AU2019373367A1 (en) 2021-05-27
JP2022509416A (ja) 2022-01-20
ECSP21038534A (es) 2021-06-30
EP3873891A1 (en) 2021-09-08
EA202190899A1 (ru) 2021-08-19
PE20211975A1 (es) 2021-10-05
CN113056461A (zh) 2021-06-29
DOP2021000081A (es) 2021-07-30
KR20210086661A (ko) 2021-07-08
CL2021001123A1 (es) 2021-10-22
AR116898A1 (es) 2021-06-23
JOP20210091A1 (ar) 2023-01-30
TW202031645A (zh) 2020-09-01
SG11202104348XA (en) 2021-05-28
BR112020013011A2 (pt) 2021-05-04
WO2020089262A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
WO2020160193A3 (en) Compounds and uses thereof
JOP20210091A1 (ar) مشتقات أريل سلفونيل بيرول كربوكساميد على هيئة عوامل تنشيط قناة بوتاسيوم Kv3
EP4241843A3 (en) Alcohol derivatives as kv7 potassium channel openers
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
PH12019550235A1 (en) Kinase inhibitors and uses thereof
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
PH12019501359A1 (en) Polymorphs
MY192425A (en) Polymorphs
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
EP4252755A3 (en) Therapeutic compounds
TN2018000372A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions.
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
PH12020550947A1 (en) Polymorphs
EP4706394A3 (en) Use of alkoxypyrazoles as nitrification inhibitors
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
ZA202109598B (en) Alcohol derivatives as kv7 potassium channel openers
JOP20210331A1 (ar) مُعَدِّلات مُستقبِل نمدا (nmda)
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
PH12019500801A1 (en) Structures and mechanism for the design of highly potent glucocorticoids
PH12021552042A1 (en) Novel potassium channel inhibitors
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.
MX2022005585A (es) Composiciones farmaceuticas.
JOP20180070B1 (ar) مثبطات إنزيم كيناز بروتين يتفاعل مع مستقبل 1